APRE -
Aprea Therapeutics, Inc. Common stock
| Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
| 1.11 0.06 (5.08%) |
--- |
--- |
0.0 (0.0%) |
0.0 (0.0%) |
0.06 (5.08%) |
--- |
0.0 (0.0%) |
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
Earnings & Ratios
- Basic EPS:
- -0.53
- Diluted EPS:
- -0.53
- Basic P/E:
- -2.2008
- Diluted P/E:
- -2.2008
- RSI(14) 1m:
- 100.0
- VWAP:
- 1.17
- RVol:
Events
| Period |
Kind |
Movement |
Occurred At |
Related News
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center
Jun 25, 2025 13:00
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update
May 14, 2025 12:00
Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
Jun 21, 2024 12:00
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
Jun 17, 2024 12:30
Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
May 28, 2024 12:45
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
May 13, 2024 20:01
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 02, 2024 13:15
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
Apr 10, 2024 16:00
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
Mar 26, 2024 11:45
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
Mar 11, 2024 12:30